SHRX — Sharp Therapeutics Balance Sheet
0.000.00%
- CA$14.09m
- CA$11.51m
Annual balance sheet for Sharp Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final |
Cash | ||||
Cash and Short Term Investments | 0.063 | 0.111 | 0.299 | 3.48 |
Net Total Receivables | — | 0.004 | 0 | — |
Prepaid Expenses | ||||
Total Other Current Assets | ||||
Total Current Assets | 0.063 | 0.125 | 0.299 | 3.52 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | — | — | — | 1.02 |
Other Long Term Assets | ||||
Total Assets | 0.063 | 0.125 | 0.299 | 4.55 |
Accounts Payable | ||||
Payable / Accrued | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 0.074 | 0.034 | 0.019 | 0.69 |
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Liabilities | 0.074 | 0.034 | 0.019 | 1.97 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Other Equity | ||||
Total Equity | -0.011 | 0.091 | 0.28 | 2.58 |
Total Liabilities & Shareholders' Equity | 0.063 | 0.125 | 0.299 | 4.55 |
Total Common Shares Outstanding |